Literature DB >> 22968924

Neonatal hyperimmune T-cell reaction mimicking T-cell non-Hodgkin's lymphoma following BCG and hepatitis B co-vaccination.

Snjezana Dotlic1, Semir Vranic, Gordana Jakovljevic, Ivana Ilic, Mirjana M Kardum-Paro, Stefan D Dojcinov.   

Abstract

We describe a case of a 2-week-old male infant who presented with a rapidly enlarging inguinal mass after having received both the bacille Calmette-Guérin (BCG) and hepatitis B vaccines at birth. The clinical picture raised suspicion of a neoplasm, and an excision biopsy was performed. It showed complete effacement of the lymph node architecture by a diffuse proliferation of monomorphic, mitotically active, and medium-sized T-cell blasts with strong expression of CD99. Coalescent necrotizing granulomas were also seen. The lymph node culture was negative for BCG. Upon expert review and additional molecular diagnostics, the initial pathological diagnosis of lymphoblastic T-cell lymphoma was changed to ectopic BCG lymphadenitis and hyperimmune post-vaccinal reaction. The atypical T-cell proliferation was most likely a result of the adjuvant effects of the co-administered vaccines. Post-vaccinal reactions usually involve the injection site or result in localized lymph node enlargements in the areas draining the inoculation site. This case highlights the importance of the clinical context for accurate interpretation of the pathological findings. In the setting of post-vaccinal lymphadenopathy, a biopsy is rarely needed but, when performed, should be interpreted with great caution.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22968924     DOI: 10.1007/s00428-012-1314-z

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  19 in total

1.  CD99 isoforms expression dictates T cell functional outcomes.

Authors:  Isabelle Alberti; Ghislaine Bernard; Alexandre K Rouquette-Jazdanian; Claudette Pelassy; Monique Pourtein; Claude Aussel; Alain Bernard
Journal:  FASEB J       Date:  2002-10-04       Impact factor: 5.191

Review 2.  Bacille Calmette-Guérin lymphadenitis.

Authors:  Jafinder S Goraya; V S Virdi
Journal:  Postgrad Med J       Date:  2002-06       Impact factor: 2.401

3.  Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination.

Authors:  Jeffrey S Kennedy; Sharon E Frey; Lihan Yan; Alan L Rothman; John Cruz; Frances K Newman; Laura Orphin; Robert B Belshe; Francis A Ennis
Journal:  J Infect Dis       Date:  2004-08-30       Impact factor: 5.226

Review 4.  Local and regional adverse reactions to BCG-SSI vaccination: a 12-month cohort follow-up study.

Authors:  M A Dommergues; F de La Rocque; C Guy; A Lécuyer; A Jacquet; N Guérin; J P Fagot; M Boucherat; Ph d'Athis; R Cohen
Journal:  Vaccine       Date:  2009-10-01       Impact factor: 3.641

5.  Pathologic findings for bacille Calmette-Guérin infections in immunocompetent and immunocompromised patients.

Authors:  L A al-Bhlal
Journal:  Am J Clin Pathol       Date:  2000-05       Impact factor: 2.493

6.  Bcg vaccination as a cause of multifocal osteomyelitis in a 12-year-old girl.

Authors:  C Moëll; T Wiebe; T Hallberg
Journal:  Acta Paediatr Scand       Date:  1983-01

7.  Spontaneous remission of acute lymphoblastic leukemia with mediastinal mass.

Authors:  A Yoruk; M Erguven; E Celiker; H Aki; C Timur; E Yuksel; H Ozkan
Journal:  Pediatr Hematol Oncol       Date:  2008 Apr-May       Impact factor: 1.969

8.  CD99 expression in T-lineage ALL: implications for flow cytometric detection of minimal residual disease.

Authors:  M N Dworzak; G Fröschl; D Printz; L De Zen; G Gaipa; R Ratei; G Basso; A Biondi; W-D Ludwig; H Gadner
Journal:  Leukemia       Date:  2004-04       Impact factor: 11.528

9.  Angiolymphoid hyperplasia with eosinophilia associated with tetanus toxoid vaccination.

Authors:  A B Akosa; M H Ali; C T Khoo; D M Evans
Journal:  Histopathology       Date:  1990-06       Impact factor: 5.087

10.  High CD99 expression in memory T and B cells in reactive lymph nodes.

Authors:  C K Park; Y K Shin; T J Kim; S H Park; G H Ahn
Journal:  J Korean Med Sci       Date:  1999-12       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.